![]() ![]() HROW offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications. Harrow Health is an eyecare pharmaceutical company, focused on the discovery, development, and commercialization of ophthalmic therapies. The Zacks Consensus Estimate for current-year earnings has improved more than 100% over the last 60 days. It has an expected earnings growth rate of more than 100% for the current year. The stock price of Arcellx has jumped 42.7% in the past four weeks. ACLX’s lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).ĪCLX is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and product candidates for solid tumor programs. Let’s discuss five out of these 21 stocks:Īrcellx is a clinical-stage biotechnology company, engaged in the development of various immunotherapies for patients with cancer and other incurable diseases. Just these few criteria narrowed down the search from over 7,700 stocks to 21. It indicates that these are strong enough in terms of price. You can see the complete list of today’s Zacks #1 Rank stocks here.Īverage Broker Rating 1 or 2: This indicates that brokers are also highly hopeful about the stock’s future performance.Ĭurrent Price greater than 5: The stocks must all be trading at a minimum of $5.Ĭurrent Price/ 52-Week High-Low Range more than 85%: This criterion filters stocks that are trading near their respective 52-week highs. Zacks Rank 1: No matter whether market conditions are good or bad, stocks with a Zacks Rank #1 (Strong Buy) have a proven history of outperformance. This lowers the risk of choosing stocks that may have drawn attention due to the overwhelming performance of the overall market in a very short period. Percentage Change Price (12 Weeks) greater than 10: This indicates that the stock has seen momentum over the last three months. Percentage Change in Price (4 Weeks) greater than zero: This criterion shows that the stock has moved higher in the last four weeks. Here’s how you should create the screen to shortlist the current as well as the potential winners. ![]() ![]() Therefore, other relevant parameters are needed to create a successful investment strategy. However, recent price strength alone cannot create magic. So, looking at stocks capable of beating the benchmark that they have set for themselves seems rational. If a stock is continuously witnessing an uptrend, there must be a solid reason or it would have probably crashed. Stocks seeing price strength recently have a high chance of carrying the momentum forward. We have primarily targeted stocks that have freshly been on a bull run. We have selected five that are likely to gain in the near term backed by a favorable Zacks Rank. Recently, several stocks have shown price strength. Our projection has shown that total earnings of the S&P 500 Index are set to decline 5.7% year over year on 2.8% higher revenues compared with a 10% year-over-year decline in earnings on 1.7% higher revenues, estimated at the beginning of the reporting cycle. corporates have presented relatively good earnings results so far despite the threat of a recession later this year. We are in the middle of the first-quarter 2023 earnings season. The terminal rate is likely to be 5.125%, which means just one 25 basis-point rate hike from the existing range of 4.75-5%. ![]() In the post-FOMC statement in March, Fed Chairman Jerome Powell said that the central bank is approaching the end of its ongoing interest rate hike regime. The major driver of this month will be the Fed’s FOMC meeting scheduled on May 2 and 3, and the first-quarter 2023 earnings season. stock markets is likely to sustain in May. Year to date, the Dow and the S&P 500 have advanced 1.6% and 7.3%, respectively. stocks markets remained in positive territory despite the threat of a near-term recession. The Nasdaq Composite also rose marginally despite a weak start.Īfter a highly disappointing 2022, U.S. The S&P 500 gained 1.5%, finishing the second positive month in a row. In April, the Dow advanced 2.5%, marking its best month since January. Wall Street completed last month on a positive note despite volatility. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |